Study of the pharmacokinetics of vancomycin in patients with impaired liver function

Journal of Infection and Chemotherapy

Volumn 5, Issue 2, 1999, Pages 104-107

  Harada, Haruhisa ^a   Miyagawa, Shinichi ^b   Kawasaki, Seiji ^b   Hayashi, Ken ^b   Kitamura, Hiroshi ^b   Katsuyama, Yoshihiko ^b   Atobe, Osamu ^b   Tada, Akihiro ^b   Zenda, Hiroshi ^b   Oguma, Takayoshi ^c  

^a National Hospital Organization   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

Impaired liver function; Pharmacokinetics; Protein binding; Vancomycin hydrochloride (VCM)

Indexed keywords

VANCOMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; MALE;

EID: 13044278310     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560050018     Document Type: Article

References (13)

1. Brown N, Ho DH, Fong KL, Bogerd L, Maksymiuk A, Bolivar R, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23:603-9.
2. Matzke GR, Zhanel GG, Gruy DR. Clinical pharmacokinetics of vancomycin. Clinical Pharmacokinetics 1986;11:257-82.
3. Metzler CM, Elfring GL, McEwen AJ. A users manual for NONLIN and associated programs. Kalamazoo: MI, The Upjohn; 1974.
4. Sedman AJ, Molitoris BA, Nakata LM, Gal J. Therapeutic drug monitoring in patients with chronic renal failure: evaluation of the Abbott TDx drug assay system. Am J Nephrol 1986;6:132-4.
5. Hosotsubo H. Rapid and specific method for the determination of vancomycin in plasma by high-performance liquid chromatography on an aminopropyl column. J Chromatogr 1989;487:421-7.
6. Nielsen HE, Hansen HE, Korsager B, Skov PE. Renal excretion of vancomycin in kidney disease. Acta Med Scand 1975;197:261-4.
7. Nakashima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for injection. Chemotherapy 1992; 40:210-24.
8. Krogstad DJ, Moellering RC Jr, Greenblatt DJ. Single-dose kinet-ics of intravenous vancomycin. Clin Pharmacol Ther 1980;20:197-201.
9. Rotschafer JC, Grossley KC, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observation in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22:391-4.
10. Cho T, Uchida E, Oguma T, Uchida N, Yasuda K, Shimada K, et al. Contribution of non-renal clearance to the elimination of vancomycin during repeated intravenous administration in elderly patients. Jpn J Clin Pharmacol Ther 1995;26:743-51.
11. Zokufa HZ, Solem LD, Rodvold KA, Crossley KB, Fischer JH, Rotschafer JC. The influence of serum albumin and α 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil 1989;10:425-8.
12. Aoki Y, Kashiwagi H. Bactericidal activity of vancomycin against methicillin-resistant Staphylococcus aureus (MRSA). Chemotherapy 1992;40:997-1004.
13. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115: 674-80.